Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Statements (2024 and earlier)

Company Profile

Business Address 500 RIVER RIDGE DRIVE
NORWOOD, MA 02062
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36,56644,22759,19766,22973,30386,121
Cash and cash equivalents8,3497,32417,00312,44425,77157,026
Short-term investments28,21736,90342,19453,78647,53329,095
Restricted cash and investments192192192192192192
Other undisclosed current assets1,5161,4467929261,7422,162
Total current assets:38,27445,86560,18167,34875,23888,476
Noncurrent Assets
Operating lease, right-of-use asset3,4863,6883,8844,0744,2584,436
Property, plant and equipment1,2741,4321,6141,7981,9892,210
Restricted cash and investments477477477477477477
Other noncurrent assets21218215513310475
Total noncurrent assets:5,4495,7806,1316,4836,8297,200
TOTAL ASSETS:43,72351,64566,31273,83182,06795,675
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,9257,7918,1738,8816,7038,193
Interest and dividends payable966
Employee-related liabilities1,707
Accounts payable1,5061,3232,1741,3741,9872,697
Accrued liabilities6,4196,4685,9994,8344,7165,496
Debt7,0165,0092,796 7,4755,178
Derivative instruments and hedges, liabilities373737134134134
Other undisclosed current liabilities1,4081,5221,6348,4551,3181,613
Total current liabilities:16,38614,35912,64017,46915,63015,118
Noncurrent Liabilities
Long-term debt and lease obligation 11,31913,97215,98414,39316,94519,380
Long-term debt, excluding current maturities 11,31913,97215,9849,38611,61213,728
Liabilities, other than long-term debt3,9986,8554,698222222
Other liabilities222,52222222222
Operating lease, liability3,9754,3334,6755,0075,3335,651
Other undisclosed noncurrent liabilities2,500     
Total noncurrent liabilities:17,81720,82720,68214,41516,96719,402
Total liabilities:34,20335,18633,32231,88432,59734,520
Equity
Equity, attributable to parent9,52116,45932,99041,94649,47061,155
Common stock000131313
Additional paid in capital428,153426,352425,196423,342421,997420,483
Accumulated other comprehensive loss(24)(68)(126)(207)(119)(170)
Accumulated deficit(418,609)(409,825)(392,081)(381,202)(372,420)(359,171)
Total equity:9,52116,45932,99041,94649,47061,155
TOTAL LIABILITIES AND EQUITY:43,72351,64566,31273,83182,06795,675

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues   97   
Operating expenses(8,189)(17,297)(10,797)(8,181)(12,340)(8,517)
Operating loss:(8,189)(17,297)(10,797)(8,181)(12,340)(8,517)
Nonoperating income (expense)595(448)(82)(600)(909)(920)
Gain (loss), foreign currency transaction, before tax(2)1186(136)(210)(268)
Other nonoperating income (expense)18323027678(209)(193)
Interest and debt expense(970)(937)(904)(811)(698)(684)
Loss from continuing operations:(8,564)(18,682)(11,783)(9,593)(13,947)(10,121)
Loss before gain (loss) on sale of properties:(9,593)(13,947)(10,121)
Other undisclosed net income (loss)(220)937904811698684
Net loss available to common stockholders, diluted:(8,784)(17,745)(10,879)(8,782)(13,249)(9,437)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(8,784)(17,745)(10,879)(8,782)(13,249)(9,437)
Other comprehensive income (loss)455881(88)50(107)
Comprehensive loss, net of tax, attributable to parent:(8,739)(17,687)(10,798)(8,869)(13,199)(9,544)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: